https://orcid.org/0000-0001-5703-3151
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
ABSTRACT
The worldwide implementation of pneumococcal conjugate vaccines (PCVs) in children has reduced the overall pneumococcal disease burden. Two PCVs are widely available for infant vaccination: the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) and the 13-valent PCV (PCV13). While these PCVs differ in serotype composition (PCV13 includes polysaccharides of serotypes 3, 6A and 19A; PHiD-CV does not), their impact on the overall pneumococcal disease burden in children is comparable. This commentary summarizes the evidence of comparability between PHiD-CV and PCV13 and explores why differences in serotype composition may not necessarily translate into a differential clinical impact. Both vaccines confer similarly high protection against disease caused by vaccine serotypes and lead to a partial replacement by non-vaccine serotypes. PHiD-CV does not protect against serotype 3 disease (not included in the vaccine) and PCV13’s effect on this serotype has been inconsistent. PHiD-CV provides some cross-protection against disease caused by vaccine-related serotype 19A but neither vaccine has fully controlled 19A disease. While protection against 19A is higher for PCV13 than PHiD-CV, replacement by non-PCV13 serotypes in settings with a PCV13 program appears to compensate for this difference. This results in a similar residual overall disease burden with both vaccines.
PLAIN LANGUAGE SUMMARY
What is the context?
The pneumococcus bacterium can cause infections of the meninges, blood, lung, middle ear and sinuses.
Two vaccines, Synflorix (GSK) and Prevnar 13 (Pfizer Inc.), are widely used to protect young children against these infections.
The vaccines’ compositions differ: Synflorix includes antigens from 10 pneumococcus strains (or “serotypes”) and Prevnar 13 from 13 serotypes.
However, both have a similar effect on the total pneumococcal disease burden in children.
What does this commentary highlight?
This commentary summarizes the evidence behind the two vaccines’ comparable impact on pneumococcal disase.
It also looks at why the vaccines have a similar effect on the total pneumococcal disease burden despite their different compositions.
What is the impact on current thinking?
Given that Synflorix and Prevnar 13 have a comparable impact on pneumococcal disease, a country’s choice between the two vaccines will depend on vaccine supply, cost, logistical factors (e.g., transport, storage, training requirements of health workers) and the local pneumococcal epidemiology.
© 2021 GlaxoSmithKline Biologicals SA. Published with license by Taylor & Francis Group, LLC
Acknowledgments
The authors would like to thank Modis for editorial assistance and manuscript coordination, on behalf of GSK: Natalie Denef provided writing assistance and Stéphanie Deroo provided publication coordination support.
Disclosure of potential conflicts of interest
P Izurieta and J Nieto Guevara are employees of the GSK group of companies and declare financial (including shares) and non-financial relationships and activities.
Author contributions
P Izurieta and J Nieto Guevara contributed to the conceptualization (structure and scope) of the paper, P Izurieta contributed to writing the original draft and both authors contributed to the review and editing of the manuscript.
Trademark statement
Synflorix is a trademark of the GSK group of companies. Prevnar/Prevenar and Prevnar 13/Prevenar 13 are trademarks of Pfizer Inc.
Supplementary Material
Supplemental data for this article can be accessed on the publisher’s website at https://doi.org/10.1080/21645515.2021.1872341.